Join Our 20,000+ Subscribers. Get Weekly News Sent To Your Email
Subscribe to our newsletter and stay updated on the latest Critical Care Medicine related news.
See Past Critical Care Newsletter issues

Subscribe to Newsletter

Crizanlizumab use lowers rates of sickle cell crises

2minutemedicine.com February 9, 2017

Patients with sickle cell disease treated with high-dose crizanlizumab experienced lower annualized rates of sickle cell crisis compared to placebo treatment, regardless of their baseline use of hydroxyurea. Those treated with high-dose crizanlizumab remained without a sickle cell crisis on average significantly longer into the study period than those treated with placebo.

inflammation study treatment trial

Impacts of Initial ICU Driving Pressure on Outcomes in Acute Hypoxemic Respiratory Failure

Effects of Surgery on Hemodynamics and Postoperative Delirium in Stanford Type A Aortic Dissection

Implementing a Bedside Percutaneous Tracheostomy and Ultrasound Gastrostomy Team Reduces Length of Stay and Hospital Costs

Predictors of Weaning Failure in Ventilated ICU Patients

Respiratory Monitoring in Mechanical Ventilation: Techniques and Applications

A Perspective on Post-Cardiac Arrest Syndrome

Heparin-induced Thrombocytopenia in the Intensive Care Setting

Intracranial Pressure & Neuromonitoring XVI

Manual of Cardiac Intensive Care

Lung Ultrasound in the Critically Ill: The BLUE Protocol

Rapid Diagnosis of MRSA

Hemodynamic Monitoring Using Echocardiography in the Critically Ill

Bedside Procedures in the ICU

Trauma Team Dynamics: A Trauma Crisis Resource Management Manual

Evidence-Based Critical Care: A Case Study Approach

Severe Trauma and Sepsis: Organ Damage and Tissue Repair

Clinical Examination Skills in the Adult Critically Ill Patient

Moderate and Deep Sedation in Clinical Practice

Basics of Mechanical Ventilation